Key Takeaways One shot a month of an experimental drug yielded promising results in a new clinical trialThe drug, called ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...